As of Friday close, Takeda Pharmaceutical Company Limited’s (NYSE:TAK) stock was down -$0.09, moving down -0.65 percent to $13.84. The average number of shares traded per day over the past five days has been 2,555,580 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.77 fall in that time frame. In the last twenty days, the average volume was 2,797,240, while in the previous 50 days, it was 2,616,598.
Since last month, TAK stock retreated -4.42%. Shares of the company fell to $13.79 on 08/05/22, the lowest level in the past month. A 52-week high of $17.31 was reached on 02/18/22 after having rallying from a 52-week low of $13.05. Since the beginning of this year, TAK’s stock price has risen by 1.54% or $0.21, and marked a new high 16 times. However, the stock has declined by -20.05% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Right now, Takeda Pharmaceutical Company Limited (TAK) has a P/E ratio of about 29.38. The stock’s beta is 0.73. Besides these, the trailing price-to-sales (P/S) ratio of 1.64, the price-to-book (PB) ratio of 0.91, and the price-to-cash flow ratio of 9.40 may also be considered.
In the recent quarter, Takeda Pharmaceutical Company Limited’s quick ratio stood at 0.70, while its current ratio was 1.20, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.68, and the total debt-to-equity ratio was 0.73. On the profitability front, the trailing twelve-month gross margin is 67.70% percent. In the recent year, EBITDA margin amounted to 33.44%, whereas operating margins totaled 10.10%. Based on annual data, TAK earned $21.91 billion in gross profit and brought in $31.76 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 3.90%. Return on equity (ROE) for the past 12 months was 3.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. During the quarter, the company generated $2.38 billion in EBITDA. The liabilities of Takeda Pharmaceutical Company Limited were 59.66 billion at the end of its most recent quarter, and its total debt was $4.6 trillion.
This quick technical analysis looks at Takeda Pharmaceutical Company Limited’s (TAK) price momentum. With a historical volatility rate of 16.82%, the RSI 9-day stood at 31.99% on 05 August.
With respect to its five-day moving average, the current Takeda Pharmaceutical Company Limited price is down by -5.27% percent or -$0.77. At present, TAK shares trade -3.89% below its 20-day simple moving average and -4.09% percent below its 100-day simple moving average. However, the stock is currently trading approximately -7.36% below its SMA50 and -1.84% below its SMA200.
Stochastic coefficient K was 4.87% and Stochastic coefficient D was 8.23%, while ATR was 0.23. Given the Stochastic reading of 4.52% for the 14-day period, the RSI (14) reading has been calculated as 38.97%. As of today, the MACD Oscillator reading stands at -0.40, while the 14-day reading stands at -0.52.
Cowen upgraded its rating on Takeda Pharmaceutical Company Limited (NYSE: TAK) to an Outperform in a note to investors on July 19, 2022. The analysts firm previously had a Market perform rating on the stock.Takeda Pharmaceutical Company Limited (TAK) has been rated Overweight by analysts. According to 0 brokerage firms, TAK is a sell, and 8 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 2 analysts rate Takeda Pharmaceutical Company Limited stock as buy, with 4 recommending it as overweight.
With a median target price of $15.64, the current consensus forecast for the stock is $13.47 – $25.81. Based on these forecasts, analysts predict Takeda Pharmaceutical Company Limited (TAK) will achieve an average price target of $16.39.